Lyell Immunopharma, Inc. — Director's Dealing 2022

Jun 10, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2022-06-08

Reporting Person: NABEL ELIZABETH G (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-08	Option (right to buy)	$5.31	A	65000	Acquired	2032-06-07	Common Stock (65000)	Direct

Footnotes

F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected
or the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person
providing continuous service through such date.